[
  {
    "ts": null,
    "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why",
    "summary": "The latest trading day saw Merck (MRK) settling at $80.4, representing a -1.36% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=89247a2624a684cef9311be86859bee414b859f31076818e27d939b6476ce308",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758577803,
      "headline": "Merck (MRK) Stock Sinks As Market Gains: Here's Why",
      "id": 136850671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The latest trading day saw Merck (MRK) settling at $80.4, representing a -1.36% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=89247a2624a684cef9311be86859bee414b859f31076818e27d939b6476ce308"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 15 Best Stocks to Invest in for Financial Stability. On September 15, 2025, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo revealed that the FDA granted Breakthrough Therapy Designation to raludotatug deruxtecan for platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment. […]",
    "url": "https://finnhub.io/api/news?id=51929efb5a3900d0759c80e8ad3b5f852ee37c785e62518d0dd708288c0a451d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758576730,
      "headline": "FDA Grants Breakthrough Therapy Designation to Merck & Co., Inc. (MRK)’s Raludotatug Deruxtecan for Platinum-Resistant Ovarian",
      "id": 136845232,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the 15 Best Stocks to Invest in for Financial Stability. On September 15, 2025, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo revealed that the FDA granted Breakthrough Therapy Designation to raludotatug deruxtecan for platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers expressing CDH6 after bevacizumab treatment. […]",
      "url": "https://finnhub.io/api/news?id=51929efb5a3900d0759c80e8ad3b5f852ee37c785e62518d0dd708288c0a451d"
    }
  },
  {
    "ts": null,
    "headline": "Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff",
    "summary": "The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.",
    "url": "https://finnhub.io/api/news?id=b9e50a51b2619b4c84241f7046a81e016745c5a31c3fb8f80a36f5b803857a67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758571696,
      "headline": "Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff",
      "id": 136845233,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration approved an injectable version of Merck's biggest moneymaker, cancer behemoth Keytruda.",
      "url": "https://finnhub.io/api/news?id=b9e50a51b2619b4c84241f7046a81e016745c5a31c3fb8f80a36f5b803857a67"
    }
  },
  {
    "ts": null,
    "headline": "FDA Clears Merck's One-Minute Cancer Shot",
    "summary": "The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for Keytruda. Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. Merck expects to have Keytruda Qlex available in the U.S. in late September. Also Read: Merck’s Exit Highlights UK Risks Losing Pharma Inves",
    "url": "https://finnhub.io/api/news?id=4a7364391c0d2ab2fa3b5e807842aab0dba3c8d6e34bc742d04c94518e2a1397",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758561837,
      "headline": "FDA Clears Merck's One-Minute Cancer Shot",
      "id": 136845234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for Keytruda. Berahyaluronidase alfa is a variant of human hyaluronidase developed and manufactured by Alteogen Inc. Merck expects to have Keytruda Qlex available in the U.S. in late September. Also Read: Merck’s Exit Highlights UK Risks Losing Pharma Inves",
      "url": "https://finnhub.io/api/news?id=4a7364391c0d2ab2fa3b5e807842aab0dba3c8d6e34bc742d04c94518e2a1397"
    }
  },
  {
    "ts": null,
    "headline": "MSD wins SC Keytruda approval, but analysts sceptical on impact",
    "summary": "Though Keytruda QLEX will be more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic competition.",
    "url": "https://finnhub.io/api/news?id=d79bea3c4d1f65b92408ea64332ae3ab0802a316481a3cfcc9800b296ce05669",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758559908,
      "headline": "MSD wins SC Keytruda approval, but analysts sceptical on impact",
      "id": 136845235,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Though Keytruda QLEX will be more patient-centric, analysts are sceptical of the drug’s capacity to stave off generic competition.",
      "url": "https://finnhub.io/api/news?id=d79bea3c4d1f65b92408ea64332ae3ab0802a316481a3cfcc9800b296ce05669"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=318fd2fc77318b34ac19dacdd1181e0d81cafa410b8d99137e011924b145f67c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758558840,
      "headline": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
      "id": 136868475,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=318fd2fc77318b34ac19dacdd1181e0d81cafa410b8d99137e011924b145f67c"
    }
  },
  {
    "ts": null,
    "headline": "Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?",
    "summary": "FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.",
    "url": "https://finnhub.io/api/news?id=90502c68dbe2237d87922d9810b7ae980dfd4bf12462e77c7a3f40c91e38b00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758550860,
      "headline": "Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?",
      "id": 136845236,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.",
      "url": "https://finnhub.io/api/news?id=90502c68dbe2237d87922d9810b7ae980dfd4bf12462e77c7a3f40c91e38b00a"
    }
  },
  {
    "ts": null,
    "headline": "3 Dirt-Cheap Stocks to Buy Right Now",
    "summary": "These stocks share several common denominators, including attractive valuations.",
    "url": "https://finnhub.io/api/news?id=f6ca2e9ef4f7abca63d7c73af7ac91d3e04376467ed0c99dbe0bea26ba4add59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758544200,
      "headline": "3 Dirt-Cheap Stocks to Buy Right Now",
      "id": 136845237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "These stocks share several common denominators, including attractive valuations.",
      "url": "https://finnhub.io/api/news?id=f6ca2e9ef4f7abca63d7c73af7ac91d3e04376467ed0c99dbe0bea26ba4add59"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Buys Obesity Drug Developer Metsera: Buy Today And Benefit From CVRs",
    "summary": "Pfizer Inc. acquires Metsera, Inc. to re-enter the obesity drug market. Click for my look at PFZ and MTSR stock and where I see value in the weight loss sector.",
    "url": "https://finnhub.io/api/news?id=5bfff513063fe49ab6c7824a71faf28231baceff3d5fefb0fa928a0b51860a29",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758536408,
      "headline": "Pfizer Buys Obesity Drug Developer Metsera: Buy Today And Benefit From CVRs",
      "id": 136842565,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299632091/image_1299632091.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. acquires Metsera, Inc. to re-enter the obesity drug market. Click for my look at PFZ and MTSR stock and where I see value in the weight loss sector.",
      "url": "https://finnhub.io/api/news?id=5bfff513063fe49ab6c7824a71faf28231baceff3d5fefb0fa928a0b51860a29"
    }
  },
  {
    "ts": null,
    "headline": "Merck unveils new €150m Irish manufacturing facility in Blarney",
    "summary": "Merck's new 3,000sqm site expands its filter manufacturing capacity in the region, and will begin production in the fourth quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=bdc81facf0f0ba5d0e3dc309eadfe6ca01631212d358bfe1d8989918bf109fc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758531881,
      "headline": "Merck unveils new €150m Irish manufacturing facility in Blarney",
      "id": 136845238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck's new 3,000sqm site expands its filter manufacturing capacity in the region, and will begin production in the fourth quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=bdc81facf0f0ba5d0e3dc309eadfe6ca01631212d358bfe1d8989918bf109fc4"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Merck: “I Think You Continue to Hold It”",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently gave takes on. Answering a caller’s query about the stock, Cramer said: “Oh, they’ve got some good stuff in the, they’ve made a couple good acquisitions. The dividend seems safe. I think Rob Davis is turning the stock around. I think you […]",
    "url": "https://finnhub.io/api/news?id=151dd8a375e7c8f18a7d8995cfb68318886033c05782d533abddfebfc20afba1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758526980,
      "headline": "Jim Cramer on Merck: “I Think You Continue to Hold It”",
      "id": 136845239,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently gave takes on. Answering a caller’s query about the stock, Cramer said: “Oh, they’ve got some good stuff in the, they’ve made a couple good acquisitions. The dividend seems safe. I think Rob Davis is turning the stock around. I think you […]",
      "url": "https://finnhub.io/api/news?id=151dd8a375e7c8f18a7d8995cfb68318886033c05782d533abddfebfc20afba1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield",
    "summary": "Merck trades at a deep discount to peers with strong profitability, Keytruda-led growth, and a 3.99% yield despite near-term risks. See why MRK stock is a strong buy.",
    "url": "https://finnhub.io/api/news?id=d23696f44c83e3b45a50e13da63b373d13a9edf350f8afa824a9509bced975d5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758520978,
      "headline": "Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield",
      "id": 136841701,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210931291/image_1210931291.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck trades at a deep discount to peers with strong profitability, Keytruda-led growth, and a 3.99% yield despite near-term risks. See why MRK stock is a strong buy.",
      "url": "https://finnhub.io/api/news?id=d23696f44c83e3b45a50e13da63b373d13a9edf350f8afa824a9509bced975d5"
    }
  },
  {
    "ts": null,
    "headline": "Fears for pharma slump as labs stand empty",
    "summary": "Britain is battling a glut of empty lab space after a string of pharmaceutical companies pulled investment from the country.",
    "url": "https://finnhub.io/api/news?id=5042137bdf3f59d86d916c387488c91e3d89d8f4d3186def1eb9d43bf50521cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758519000,
      "headline": "Fears for pharma slump as labs stand empty",
      "id": 136843831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Britain is battling a glut of empty lab space after a string of pharmaceutical companies pulled investment from the country.",
      "url": "https://finnhub.io/api/news?id=5042137bdf3f59d86d916c387488c91e3d89d8f4d3186def1eb9d43bf50521cc"
    }
  }
]